{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T02:48:37Z","timestamp":1760150917700,"version":"build-2065373602"},"reference-count":44,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2022,1,27]],"date-time":"2022-01-27T00:00:00Z","timestamp":1643241600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JPM"],"abstract":"<jats:p>Pyoderma gangrenosum (PG) is a rare and chronic neutrophil inflammation belonging to the spectrum of autoinflammatory disorders. Immunosuppressive therapy is the cornerstone of successful treatment. However, due to the global COVID-19 pandemic, physicians struggle with therapeutic strategies during infection. This paper describes the case of a 58-year-old patient with a very painful, rapidly increasing wound on his right foot, which was diagnosed as pyoderma gangrenosum. Five weeks after the initial treatment with high-dose immunosuppressives (combination therapy with cyclosporine A and systemic methylprednisolone), he became infected with COVID-19. Reduction in the immunosuppressive dosage proved effective, as the patient recovered from COVID-19 without any complication and showed rapid wound healing.<\/jats:p>","DOI":"10.3390\/jpm12020173","type":"journal-article","created":{"date-parts":[[2022,1,27]],"date-time":"2022-01-27T22:00:56Z","timestamp":1643320856000},"page":"173","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Dealing with Corticosteroid and High-Dose Cyclosporine Therapy in a Pyoderma Gangrenosum Patient Contracting a COVID-19 Infection"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6162-7008","authenticated-orcid":false,"given":"Marcella Ricardis","family":"May","sequence":"first","affiliation":[{"name":"Department of Dermatology and Allergology, University Hospital of the RWTH Aachen University, 52074 Aachen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2704-4754","authenticated-orcid":false,"given":"Albert","family":"R\u00fcbben","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergology, University Hospital of the RWTH Aachen University, 52074 Aachen, Germany"},{"name":"Department of Dermatology, St. Nikolaus Hospital, 4700 Eupen, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Lennertz","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, St. Nikolaus Hospital, 4700 Eupen, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luk","family":"Vanstreels","sequence":"additional","affiliation":[{"name":"Department of Dermatology, St. Nikolaus Hospital, 4700 Eupen, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2911-1025","authenticated-orcid":false,"given":"Marike","family":"Leijs","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergology, University Hospital of the RWTH Aachen University, 52074 Aachen, Germany"},{"name":"Department of Dermatology, St. Nikolaus Hospital, 4700 Eupen, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,1,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Yen, C.-C., Lin, S.-Y., Chen, S.-C., Chiu, Y.-W., Chang, J.-M., and Hwang, S.-J. (2021). COVID-19 vaccines in patients with maintenance hemodialysis. J. Pers. Med., 11.","DOI":"10.3390\/jpm11080789"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1111\/bjd.14691","article-title":"Pyoderma gangrenosum and its syndromic forms: Evidence for a link with autoinflammation","volume":"175","author":"Marzano","year":"2016","journal-title":"Br. J. Dermatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1002\/phar.2410","article-title":"Managing COVID-19 in renal transplant recipients: A review of recent literature and case supporting corticosteroid-sparing immunosuppression","volume":"40","author":"Johnson","year":"2020","journal-title":"Pharmacother. J. Hum. Pharmacol. Drug Ther."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e315","DOI":"10.1016\/j.jaad.2020.06.990","article-title":"Using cyclosporine in the COVID era: An emergent need for caution","volume":"83","author":"Khurana","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_5","unstructured":"World Health Organization (WHO) (2020). Corticosteroids for COVID-19. Living Guid, WHO."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Sun, Y., Zhou, J., and Ye, K. (2021). White blood cells and severe COVID-19: A mendelian randomization study WBC COVID-19 SNPs associated with WBC SNPs associated with COVID-19. J. Pers. Med., 11.","DOI":"10.3390\/jpm11030195"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(20)30566-3","article-title":"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study","volume":"395","author":"Zhou","year":"2020","journal-title":"Lancet"},{"key":"ref_8","unstructured":"Deutsche Dermatologische Gesellschaft, B. (2021, November 28). Deutsche Dermatologische Gesellschaft B. S1-Leitlinie Pyoderma Gangrenosum. 2020. AWMF. Available online: https:\/\/www.awmf.org\/uploads\/tx_szleitlinien\/013-091l_S1_Pyoderma-gangrenosum_2020-10_1.pdf."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1111\/iwj.12939","article-title":"Epidemiology of pyoderma gangrenosum: Results from an Italian prospective multicentre study","volume":"15","author":"Monari","year":"2018","journal-title":"Int. Wound J."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/S0190-9622(96)90428-4","article-title":"Pyoderma gangrenosum: Classification and management","volume":"34","author":"Powell","year":"1996","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/medicina55090578","article-title":"The skin in celiac disease patients: The other side of the coin","volume":"55","author":"Abenavoli","year":"2019","journal-title":"Medicina"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1001\/jamadermatol.2017.5980","article-title":"Diagnostic criteria of ulcerative pyoderma gangrenosum: A Delphi consensus of international experts","volume":"154","author":"Maverakis","year":"2018","journal-title":"JAMA Dermatol."},{"key":"ref_13","first-page":"615","article-title":"The PARACELSUS score: A novel diagnostic tool for pyoderma gangrenosum","volume":"180","author":"Wollina","year":"2018","journal-title":"Br. J. Dermatol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1111\/j.1365-2249.2010.04201.x","article-title":"Role of inflammatory cells, cytokines and matrix metalloproteinases in neutrophil-mediated skin diseases","volume":"162","author":"Marzano","year":"2010","journal-title":"Clin. Exp. Immunol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.jaad.2015.06.021","article-title":"Pathophysiology of pyoderma gangrenosum (PG): An updated review","volume":"73","author":"Braswell","year":"2015","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_16","first-page":"367","article-title":"Pyoderma gangrenosum: A review of updates in diagnosis, pathophysiology and management","volume":"4","author":"Skopis","year":"2021","journal-title":"J"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Wang, E.A., Steel, A., Luxardi, G., Mitra, A., Patel, F., Cheng, M.Y., Wilken, R., Kao, J., De Ga, K., and Sultani, H. (2018). Classic ulcerative pyoderma gangrenosum is a T Cell-Mediated disease targeting follicular adnexal structures: A hypothesis based on molecular and clinicopathologic studies. Front. Immunol., 8.","DOI":"10.3389\/fimmu.2017.01980"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1093\/hmg\/11.8.961","article-title":"Mutations in CD2BP1 disrupt binding to PTP PEST and are responsible for PAPA syndrome, an autoinflammatory disorder","volume":"11","author":"Wise","year":"2002","journal-title":"Hum. Mol. Genet."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/s41577-020-0331-4","article-title":"Pathological inflammation in patients with COVID-19: A key role for monocytes and macrophages","volume":"20","author":"Merad","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1001\/jamainternmed.2020.3313","article-title":"Is a \u201cCytokine Storm\u201d relevant to COVID-19?","volume":"180","author":"Sinha","year":"2020","journal-title":"JAMA Intern. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1001\/jama.2020.17052","article-title":"Cytokine levels in critically Ill patients with COVID-19 and other conditions","volume":"324","author":"Kox","year":"2020","journal-title":"JAMA"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jaci.2020.10.007","article-title":"Factors associated with adverse COVID-19 outcomes in patients with psoriasis\u2014Insights from a global registry\u2013based study","volume":"147","author":"Mahil","year":"2021","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1111\/jdv.17075","article-title":"Position statement for a pragmatic approach to immunotherapeutics in patients with in flammatory skin diseases during the coronavirus disease 2019 pandemic and beyond","volume":"35","author":"Beecker","year":"2021","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/ajd.13313","article-title":"COVID-19 and the use of immunomodulatory and biologic agents for severe cutaneous disease: An Australian\/New Zealand consensus statement","volume":"61","author":"Wang","year":"2020","journal-title":"Australas. J. Dermatol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"100591","DOI":"10.1016\/j.eclinm.2020.100591","article-title":"Clinical characteristics and outcomes among hospitalized adults with severe COVID-19 admitted to a tertiary medical center and receiving antiviral, antimalarials, glucocorticoids, or immunomodulation with tocilizumab or cyclosporine: A retrospective observational study (COQUIMA cohort)","volume":"28","year":"2020","journal-title":"EClinicalMedicine"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1099\/vir.0.034983-0","article-title":"Communication cyclosporin A inhibits the replication of diverse coronaviruses","volume":"92","author":"Thiel","year":"2011","journal-title":"J. Gen. Virol."},{"key":"ref_27","first-page":"1","article-title":"A living WHO guideline on drugs for covid-19","volume":"370","author":"Rochwerg","year":"2020","journal-title":"BMJ"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2975","DOI":"10.1111\/ajt.16250","article-title":"Cyclosporine and COVID-19: Risk or favorable?","volume":"20","author":"Poulsen","year":"2020","journal-title":"Am. J. Transpl."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"de Almeida, S.M.V., Soares, J.C.S., dos Santos, K.L., Alves, J.E.F., Ribeiro, A.G., Jacob, \u00cd.T.T., da Silva Ferreira, C.J., Santos, J.C.D., de Oliveira, J.F., and de Lima, M.D.C.A. (2020). COVID-19 therapy: What weapons do we bring into battle?. Bioorg. Med. Chem., 28.","DOI":"10.1016\/j.bmc.2020.115757"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Khurana, A., and Saxena, S. (2020). Immunosuppressive agents for dermatological indications in the ongoing COVID-19 pandemic: Rationalizing use and clinical applicability. Dermatol. Ther., 33.","DOI":"10.1111\/dth.13639"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1093\/clinids\/11.5.677","article-title":"Infection and cyclosporine","volume":"11","author":"Kim","year":"1989","journal-title":"Rev. Infect. Dis."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e151","DOI":"10.1016\/j.jaad.2020.04.153","article-title":"Cyclosporine therapy during the COVID-19 pandemic","volume":"83","author":"Rudnicka","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_33","first-page":"140","article-title":"Treatment of lupus with corticosteroids","volume":"10","author":"Chatham","year":"2001","journal-title":"SAGE J."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Tsokos, G.C. (2000). Principles of Molecular Rheumatology, Humana Press.","DOI":"10.1385\/1592590187"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13054-020-03014-1","article-title":"Cyclosporine A: A valid candidate to treat COVID-19 patients with acute respiratory failure?","volume":"24","author":"Cour","year":"2020","journal-title":"Crit. Care"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Fang, R., Wang, J., Jiang, X.-Y., Wang, S.-H., Cheng, H., and Zhou, Q. (2021). Case report: A novel mutation in NFKB1 associated with pyoderma gangrenosum. Front. Genet., 10.","DOI":"10.3389\/fgene.2021.673453"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1002\/jmv.27357","article-title":"Do high-dose corticosteroids improve outcomes in hospitalized COVID-19 patients?","volume":"1","author":"Kumar","year":"2022","journal-title":"J. Med. Virol."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"McPHIE, M.L., and Kirchhof, M.G. (2020). Pyoderma gangrenosum treated with secukinumab: A case report. SAGE Open Med. Case Rep., 1.","DOI":"10.1177\/2050313X20940430"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Vallerand, I.A., and Hardin, J. (2019). Ustekinumab for the treatment of recalcitrant pyoderma gangrenosum: A case report. SAGE Open Med. Case Rep., 1.","DOI":"10.1177\/2050313X19845206"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s13671-018-0224-y","article-title":"Pyoderma Gangrenosum: What Do We Know Now?","volume":"7","author":"McKenzie","year":"2018","journal-title":"Curr. Dermatol. Rep."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1111\/bjd.14037","article-title":"Canakinumab in adults with steroid-refractory pyoderma gangrenosum","volume":"173","author":"Kolios","year":"2015","journal-title":"Br. J. Dermatol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1111\/j.1365-2133.2009.09404.x","article-title":"Targeted treatment of pyoderma gangrenosum in PAPA (pyogenic arthritis, pyoderma gangrenosum and acne) syndrome with the recombinant human interleukin-1 receptor antagonist anakinra","volume":"161","author":"Brenner","year":"2009","journal-title":"Br. J. Dermatol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.cgh.2018.10.047","article-title":"Tofacitinib for the treatment of pyoderma gangrenosum","volume":"17","author":"Kochar","year":"2019","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_44","first-page":"504","article-title":"Successful therapy for pyoderma gangrenosum with a Janus kinase 2 inhibitor","volume":"179","author":"Nasifoglu","year":"2018","journal-title":"Br. J. Dermatol."}],"container-title":["Journal of Personalized Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4426\/12\/2\/173\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:08:51Z","timestamp":1760134131000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4426\/12\/2\/173"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,27]]},"references-count":44,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,2]]}},"alternative-id":["jpm12020173"],"URL":"https:\/\/doi.org\/10.3390\/jpm12020173","relation":{},"ISSN":["2075-4426"],"issn-type":[{"type":"electronic","value":"2075-4426"}],"subject":[],"published":{"date-parts":[[2022,1,27]]}}}